Actively Recruiting
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Led by Fudan University · Updated on 2026-04-24
238
Participants Needed
1
Research Sites
620 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to investigate whether adjuvant radiotherapy after complete resection has a better survival for stage II or III thymoma.
CONDITIONS
Official Title
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Pathologically confirmed Masaoka stage II or III thymoma
- Adequate bone marrow, liver, and kidney function
- Complete resection of thymoma performed within the past 3 months
- Provided written informed consent
You will not qualify if you...
- Presence of distant metastases
- Previous radiotherapy or chemotherapy
- History of malignancy within the past 5 years, except carcinoma in situ of the cervix
- Active clinical lung infection
- Pregnant or nursing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kailiang Wu
Shanghai, Shanghai Municipality, China, 20032
Actively Recruiting
Research Team
K
Kailiang Wu, MD.PhD.
CONTACT
X
Xingwen Fan, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here